Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817
F. Barlesi1, C. Audigier-Valette2, E. Felip3, T.-E. Ciuleanu4, K. Jao5, E. Rijavec6, L. Urban7, J.-S. Aucoin8, C. Zannori9, K. Vermaelen10, O. Arén Frontera11, N. Ready12, A. Curioni13, H. Linardou14, E. Poddubskaya15, J.R. Fischer16, R. Pillai17, S. Li18, A. Acevedo19, L. Paz-Ares20
1Multidisciplinary Oncology and Therapeutic Innovations, Aix-Marseille Université; CNRS, INSERM, CRCM; Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France
2Pulmonology Department, Hôpital Sainte-Musse, Toulon, France
3Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
4Medical Oncology Department, The Oncology Institute Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania
5Department of Hematology and Oncology, Hôpital du Sacré-Cœur de Montréal, Montreal, QC, Canada
6Lung Cancer Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genoa, Italy
7Department of Thoracic Malignancies, Matrahaza University and Teaching Hospital, Matrahaza, Hungary
8Hematology and Oncology, Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, QC, Canada
9UOC Oncologia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy
10Pulmonary Medicine, Ghent University Hospital, Ghent, Belgium
11Department of Medical Oncology, Centro Internacional de Estudios Clinicos, Santiago, Chile
12Medical Oncology, Duke Cancer Center, Durham, NC, USA
13Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
14Oncology Unit, Metropolitan Hospital, Athens, Greece
15Oncological Department, VitaMed LLC, Moscow, Russian Federation
16Department of Internal Medicine and Oncology, Löwenstein Clinic GmbH, Löwenstein, Germany
17Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
18GBS Biostatistics/Global Biometric Sciences Team, Bristol-Myers Squibb, Princeton, NJ, USA
19Clinical Development/Clinical Trial Lead - Metastatic NSCLC Program, Bristol-Myers Squibb, Princeton, NJ, USA
20Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
Thông tin
Thông tin xuất bản
Annals of Oncology
Tập 30
xi33-xi34
Thông tin tác giả